{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:31:32Z","timestamp":1793939492020,"version":"4.8.0"},"reference-count":48,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"\n Importance<\/jats:title>\n Both tumor-infiltrating lymphocytes (TILs) assessment and immune-related gene expression signatures by RNA profiling predict higher pathologic complete response (pCR) and improved event-free survival (EFS) in patients with early-stage ERBB2\/HER2-positive breast cancer. However, whether these 2 measures of immune activation provide similar or additive prognostic value is not known.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the prognostic ability of TILs and immune-related gene expression signatures, alone and in combination, to predict pCR and EFS in patients with early-stage ERBB2\/HER2-positive breast cancer treated in 2 clinical trials.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n In this prognostic study, a correlative analysis was performed on the Cancer and Leukemia Group B (CALGB) 40601 trial and the PAMELA trial. In the CALGB 40601 trial, 305 patients were randomly assigned to weekly paclitaxel with trastuzumab, lapatinib, or both for 16 weeks. The primary end point was pCR, with a secondary end point of EFS. In the PAMELA trial, 151 patients received neoadjuvant treatment with trastuzumab and lapatinib for 18 weeks. The primary end point was the ability of the HER2-enriched subtype to predict pCR. The studies were conducted from October 2013 to November 2015 (PAMELA) and from December 2008 to February 2012 (CALGB 40601). Data analyses were performed from June 1, 2020, to January 1, 2022.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Immune-related gene expression profiling by RNA sequencing and TILs were assessed on 230 CALGB 40601 trial pretreatment tumors and 138 PAMELA trial pretreatment tumors. The association of these biomarkers with pCR (CALGB 40601 and PAMELA) and EFS (CALGB 40601) was studied by logistic regression and Cox analyses.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The median age of the patients was 50 years (IQR, 42-50 years), and 305 (100%) were women. Of 202 immune signatures tested, 166 (82.2%) were significantly correlated with TILs. In both trials combined, TILs were significantly associated with pCR (odds ratio, 1.01; 95% CI, 1.01-1.02;\n P<\/jats:italic>\n \u2009=\u2009.02). In addition to TILs, 36 immune signatures were significantly associated with higher pCR rates. Seven of these signatures outperformed TILs for predicting pCR, 6 of which were B-cell related. In a multivariable Cox model adjusted for clinicopathologic factors, including PAM50 intrinsic tumor subtype, the immunoglobulin G signature, but not TILs, was independently associated with EFS (immunoglobulin G signature\u2013adjusted hazard ratio, 0.63; 95% CI, 0.42-0.93;\n P<\/jats:italic>\n \u2009=\u2009.02; TIL-adjusted hazard ratio, 1.00; 95% CI, 0.98-1.02;\n P<\/jats:italic>\n \u2009=\u2009.99).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this study suggest that multiple B-cell\u2013related signatures were more strongly associated with pCR and EFS than TILs, which largely represent T cells. When both TILs and gene expression are available, the prognostic value of immune-related signatures appears to be superior.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.6288","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T11:32:19Z","timestamp":1672918339000},"page":"490","source":"Crossref","is-referenced-by-count":86,"title":["Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2\/HER2-Positive Breast Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Aranzazu","family":"Fernandez-Martinez","sequence":"first","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"Department of Genetics, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Pascual","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"Department of Medical Oncology, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"},{"name":"Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain"},{"name":"SOLTI Breast Cancer Cooperative Group, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baljit","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pathology, White Plains Hospital, White Plains, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Nuciforo","sequence":"additional","affiliation":[{"name":"Molecular Oncology Laboratory, Vall d\u2019Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim U.","family":"Rashid","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla V.","family":"Ballman","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Hoadley","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"Department of Genetics, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Spears","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Pare","sequence":"additional","affiliation":[{"name":"Reveal Genomics, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Chic","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"},{"name":"Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain"},{"name":"SOLTI Breast Cancer Cooperative Group, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Krop","sequence":"additional","affiliation":[{"name":"Yale Cancer Center, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Partridge","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[{"name":"International Breast Cancer Center, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Llombart-Cussac","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Arnau de Vilanova, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[{"name":"Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain"},{"name":"SOLTI Breast Cancer Cooperative Group, Barcelona, Spain"},{"name":"Reveal Genomics, Barcelona, Spain"},{"name":"Department of Medicine, University of Barcelona, Barcelona, Spain"},{"name":"Breast Cancer Unit, IOB-Quir\u00f3nSalud, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Perou","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"Department of Genetics, University of North Carolina, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill"},{"name":"Division of Medical Oncology, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9816","key":"coi220083r1","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"6","key":"coi220083r2","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1200\/JCO.2015.62.1268","article-title":"Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib.","volume":"34","author":"Carey","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi220083r3","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","article-title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.","volume":"14","author":"Robidoux","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi220083r4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"16","key":"coi220083r5","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1200\/JCO.2011.39.0823","article-title":"Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2\u2013positive operable breast cancer: results of the randomized phase II CHER-LOB study.","volume":"30","author":"Guarneri","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi220083r6","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"12","key":"coi220083r7","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi220083r8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"coi220083r9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer.","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"coi220083r10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2\u2013positive breast cancer: results from the randomized phase III Adjuvant Lapatinib and\/or Trastuzumab Treatment Optimization Trial.","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi220083r11","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(13)70477-7","article-title":"The immune system and response to HER2-targeted treatment in breast cancer.","volume":"15","author":"Bianchini","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"coi220083r12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"coi220083r13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial.","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"coi220083r14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/annonc\/mdx647","article-title":"A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.","volume":"29","author":"Nuciforo","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"coi220083r15","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","article-title":"Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.","volume":"27","author":"Dieci","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"coi220083r16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"coi220083r17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/jnci\/djab057","article-title":"Tumor cellularity and infiltrating lymphocytes as a survival surrogate in HER2-positive breast cancer.","volume":"114","author":"Chic","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"coi220083r18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/annonc\/mdz047","article-title":"The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.","volume":"30","author":"Barroso-Sousa","year":"2019","journal-title":"Ann Oncol"},{"issue":"14","key":"coi220083r19","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1158\/1078-0432.CCR-13-3368","article-title":"Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.","volume":"20","author":"Iglesia","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7","key":"coi220083r20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry.","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"2","key":"coi220083r21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2016.3824","article-title":"RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial.","volume":"3","author":"Fumagalli","year":"2017","journal-title":"JAMA Oncol"},{"issue":"35","key":"coi220083r22","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.20.01276","article-title":"Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast cancer.","volume":"38","author":"Fernandez-Martinez","year":"2020","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi220083r23","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1200\/JCO.2011.39.5624","article-title":"Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.","volume":"30","author":"Ignatiadis","year":"2012","journal-title":"J Clin Oncol"},{"key":"coi220083r24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1755-8794-4-3","article-title":"Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.","volume":"4","author":"Fan","year":"2011","journal-title":"BMC Med Genomics"},{"key":"coi220083r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"4","key":"coi220083r26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1470-2045(17)30021-9","article-title":"HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.","volume":"18","author":"Llombart-Cussac","year":"2017","journal-title":"Lancet Oncol"},{"issue":"15","key":"coi220083r27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1200\/JCO.2018.36.15_suppl.509","article-title":"HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: a combined analysis of TBCRC006\/023 and PAMELA trials.","volume":"36","author":"Prat","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi220083r28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner.","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"4","key":"coi220083r29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression.","volume":"14","author":"Patro","year":"2017","journal-title":"Nat Methods"},{"key":"coi220083r30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1471-2105-11-94","article-title":"Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments.","volume":"11","author":"Bullard","year":"2010","journal-title":"BMC Bioinformatics"},{"issue":"480","key":"coi220083r31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1198\/016214507000001120","article-title":"Distance-weighted discrimination.","volume":"102","author":"Marron","year":"2007","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"coi220083r32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/rssb.12244","article-title":"Another look at distance-weighted discrimination.","volume":"80","author":"Wang","year":"2018","journal-title":"J R Stat Soc Series B Stat Methodol"},{"issue":"5","key":"coi220083r35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles.","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"issue":"16","key":"coi220083r36","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK).","volume":"97","author":"McShane","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"coi220083r37","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.1073\/pnas.091062498","article-title":"Significance analysis of microarrays applied to the ionizing radiation response.","volume":"98","author":"Tusher","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"coi220083r38","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias.","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi220083r39","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi220083r40","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.cell.2019.10.028","article-title":"B cells and T follicular helper cells mediate response to checkpoint inhibitors in high mutation burden mouse models of breast cancer.","volume":"179","author":"Hollern","year":"2019","journal-title":"Cell"},{"issue":"1","key":"coi220083r41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/jnci\/djz042","article-title":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.","volume":"112","author":"Prat","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"coi220083r42","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdz076","article-title":"A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.","volume":"30","author":"Veeraraghavan","year":"2019","journal-title":"Ann Oncol"},{"issue":"11","key":"coi220083r43","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S1470-2045(20)30450-2","article-title":"A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.","volume":"21","author":"Prat","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi220083r44","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1245\/s10434-016-5173-8","article-title":"Interobserver agreement between pathologists assessing tumor-infiltrating lymphocytes (TILs) in breast cancer using methodology proposed by the International TILs Working Group.","volume":"23","author":"Swisher","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"coi220083r45","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1080\/0284186X.2017.1403040","article-title":"Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.","volume":"57","author":"Tramm","year":"2018","journal-title":"Acta Oncol"},{"issue":"10","key":"coi220083r46","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/modpathol.2016.109","article-title":"Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the International Immuno-oncology Biomarker Working Group.","volume":"29","author":"Denkert","year":"2016","journal-title":"Mod Pathol"},{"issue":"9","key":"coi220083r47","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2\u2013positive and triple-negative primary breast cancers.","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi220083r48","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer.","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"coi220083r33","author":"Carmichael","year":"2021"},{"key":"coi220083r34","doi-asserted-by":"crossref","unstructured":"Fernandez-Martinez? A. Prognostic value of immune gene-expression signatures versus tumor-infiltrating lymphocytes in early-stage HER2-positive breast cancer: a correlative analysis of CALGB 40601 and PAMELA trials. September 1, 2022. Accessed November 17, 2022. https:\/\/github.com\/afernan4\/iGES_scores","DOI":"10.1016\/j.annonc.2021.08.401"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2800243\/jamaoncology_fernandezmartinez_2023_oi_220083_1681755678.08799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T12:44:16Z","timestamp":1681994656000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2800243"}},"subtitle":["A Correlative Analysis of the CALGB 40601 and PAMELA Trials"],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.6288","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}